Metfez-V-500

Description

 

Metfez-V-500 contains Metformin HCl 500 mg and Vildagliptin 50 mg in tablet form. This combination brings together two oral antidiabetic medicines with complementary actions. Metformin helps reduce glucose production by the liver and improves insulin sensitivity, while Vildagliptin helps regulate blood glucose by enhancing glucose-dependent insulin release and reducing inappropriate glucagon secretion. Together, they may help improve glycaemic control in adults with type 2 diabetes mellitus when prescribed alongside appropriate diet and exercise.

For related diabetic and cardiovascular formulations, explore the Medhexa Pharma product range for pharmaceutical products and business enquiries.

Therapeutic Segment

Anti-Diabetic Therapy | Type 2 Diabetes Management | DPP-4 Inhibitors | Biguanides | Blood Glucose Control

Uses of Metfez-V-500

Healthcare professionals may prescribe Metfez-V-500 as part of an individualized treatment plan for:

• Type 2 diabetes mellitus
• Inadequate blood glucose control with diet and exercise alone
• Patients requiring combination therapy with Metformin and Vildagliptin
• Improving glycaemic control when treatment with either medicine alone does not provide adequate control
• Long-term blood glucose management as part of an appropriate diabetes-care plan

Metfez-V-500 is intended for type 2 diabetes and does not replace appropriate diet, physical activity or regular diabetes monitoring.

Key Benefits of Metfez-V-500

• Dual-action formulation: Combines Metformin and Vildagliptin through complementary mechanisms.
• Blood Glucose Support: Helps improve glycaemic control in adults with type 2 diabetes.
• Metformin 500 mg: Helps reduce hepatic glucose production and improve insulin sensitivity.
• Vildagliptin 50 mg: Supports glucose-dependent insulin release and helps regulate glucagon secretion.
• Combination Convenience: Provides two oral antidiabetic medicines in one tablet.
• Oral Dosage Form: Provides a convenient tablet formulation for prescribed diabetes therapy.

How Metfez-V-500 Works

Metformin HCl belongs to the biguanide class. It primarily reduces glucose production by the liver. It also improves insulin sensitivity, which helps the body use glucose more effectively.

Vildagliptin belongs to the DPP-4 inhibitor class. It inhibits the DPP-4 enzyme, which increases the activity of incretin hormones. These hormones help the pancreas release insulin when blood glucose levels rise and reduce glucagon secretion when glucose levels are elevated.

Therefore, Metfez-V-500 combines two complementary mechanisms to support blood glucose control.

Common Side Effects of Metfez-V-500

Some people may experience side effects, particularly gastrointestinal effects associated with Metformin. Possible effects include:

• Nausea
• Diarrhoea
• Vomiting
• Abdominal discomfort
• Stomach pain
• Loss of appetite
• Headache
• Dizziness
• Indigestion
• Changes in taste

Metformin-related digestive symptoms may become less troublesome as the body adjusts to treatment.

Important Safety Information

Use Metfez-V-500 only according to the advice of a qualified healthcare professional.

Kidney Function

Kidney function should be assessed before and during treatment as appropriate. Metformin requires particular consideration of renal function because reduced kidney clearance can increase the risk of accumulation and lactic acidosis.

Tell your doctor if you have kidney disease or any condition that may affect kidney function.

Lactic Acidosis

Metformin can rarely cause lactic acidosis, a serious medical condition. Seek urgent medical attention if you develop unusual weakness, severe tiredness, breathing difficulty, persistent vomiting, abdominal discomfort or other concerning symptoms.

Liver Function

Vildagliptin can affect liver enzymes in some patients. Healthcare professionals may assess liver function before starting treatment and monitor it when clinically appropriate.

Tell your doctor if you have liver disease or develop symptoms such as persistent nausea, loss of appetite, abdominal discomfort, dark urine or yellowing of the skin or eyes.

Pancreatitis

Vildagliptin has been associated with pancreatitis in rare cases. Seek medical attention if you develop persistent, severe abdominal pain that may extend to the back, particularly if accompanied by vomiting.

Vitamin B12

Long-term Metformin treatment can reduce Vitamin B12 levels in some patients. Healthcare professionals may monitor B12 levels when clinically appropriate, particularly when symptoms or risk factors suggest deficiency.

Low Blood Sugar

Metformin and Vildagliptin have a relatively low risk of hypoglycaemia when used alone. However, the risk can increase when the combination is used with insulin or medicines such as sulfonylureas.

Drug Interactions

Tell your healthcare professional about all prescription medicines, over-the-counter medicines, vitamins and supplements you use. Particular attention may be required with medicines that affect kidney function, blood glucose or the metabolism of either component.

Inform your healthcare professional before undergoing imaging procedures involving iodinated contrast media, as Metformin may need temporary interruption depending on kidney function and the procedure.

Pregnancy and Breastfeeding

Discuss pregnancy, planned pregnancy or breastfeeding with your healthcare professional before using Metfez-V-500. Your doctor can determine whether this combination is appropriate and whether another diabetes-management approach is required.

For additional information about Vildagliptin, refer to the European Medicines Agency information on Galvus.

Dosage & Administration

Take Metfez-V-500 exactly as prescribed by your healthcare professional.

The appropriate regimen depends on the patient’s blood glucose control, previous diabetes treatment, kidney and liver function, tolerability and other clinical factors. Therefore, do not change the dose or frequency yourself.

Vildagliptin-containing combination therapy is generally administered according to the strength and dosing schedule selected by the healthcare professional. Metformin-containing products are commonly taken with meals to reduce gastrointestinal discomfort.

Swallow the tablet with water according to the prescribed instructions. Do not take additional tablets if a dose is missed unless your healthcare professional specifically advises you to do so.

Continue appropriate diet, physical activity and blood glucose monitoring as advised by your diabetes-care team.

Storage

• Store Metfez-V-500 in a cool, dry place.
• Protect the tablets from excessive heat and moisture.
• Keep the tablets in their original ALU-ALU packaging until use.
• Protect from direct sunlight.
• Keep out of the sight and reach of children.
• Do not use the product after the expiry date printed on the pack.